To test the neuroendocrine response to low-dose (12.5 mg) parenteral CMI in disorders where serotonin has been implicated (e.g., Tourette's disorder, anxiety disorders, major depression) to determine if it can discriminate patient's from controls.
Showing the most recent 10 out of 395 publications